Skip to main content

Drug Interactions between tapentadol and tirzepatide

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

tapentadol tirzepatide

Applies to: tapentadol and tirzepatide

Tirzepatide may affect the absorption of oral medications, as it can delay the emptying of stomach content into the intestines. This may impact blood levels and/or the time that it takes for tapentadol to become most effective, if tapentadol is being administered by mouth or directly into the stomach via a feeding tube. These effects are most apparent at the start of treatment with tirzepatide or after a dose increase and tend to diminish the longer that you are on a stable regimen of tirzepatide. Contact your doctor if you have any questions or notice a change in how any of your oral medications are working. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Drug and food/lifestyle interactions

Major

tapentadol food/lifestyle

Applies to: tapentadol

Consumer information for this interaction is not currently available.

GENERALLY AVOID: Alcohol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics including tapentadol. Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills. In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.

GENERALLY AVOID: Consumption of alcohol while taking extended-release formulations of tapentadol may cause rapid release of the drug, resulting in high systemic levels of tapentadol that may be potentially lethal even in opioid-tolerant patients. Alcohol appears to disrupt the extended-release mechanism, causing 'dose-dumping' into the bloodstream. A clinical study evaluated healthy volunteers administered a single dose of extended-release tapentadol (100 mg or 250 mg) with 240 mL of 40% alcohol. The mean peak tapentadol concentration (Cmax) was 48% higher when alcohol was combined with the 100 mg dose and 28% higher when alcohol was combined with the 250 mg dose, as compared to control. Additionally, the systemic exposure (AUC) of tapentadol increased by 16-17% when combined with alcohol.

MANAGEMENT: Patients taking extended-release formulations of tapentadol should not consume alcohol or use medications that contain alcohol. In general, narcotics such as tapentadol should not be combined with alcohol. Modified and/or extended-release tapentadol formulations must also be swallowed whole and not crushed, chewed or divided.

Moderate

tirzepatide food/lifestyle

Applies to: tirzepatide

Tirzepatide may affect the absorption of other medications that you take by mouth. In some cases, this may affect how well and/or how fast those medications work, or it may make no difference. Talk to a healthcare provider if you have any questions or concerns, and contact your doctor if your symptoms worsen or your condition changes. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer